Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://aptdtoa.com
Are you over 18 and want to see adult content?
A complete backup of https://gayromeo.com
Are you over 18 and want to see adult content?
A complete backup of https://kasta.ua
Are you over 18 and want to see adult content?
A complete backup of https://southwestern.edu
Are you over 18 and want to see adult content?
A complete backup of https://iafor.org
Are you over 18 and want to see adult content?
A complete backup of https://spravka-dostavka-online.com
Are you over 18 and want to see adult content?
A complete backup of https://hacker-motor-shop.com
Are you over 18 and want to see adult content?
A complete backup of https://furiousfanboys.com
Are you over 18 and want to see adult content?
A complete backup of https://netsec.news
Are you over 18 and want to see adult content?
A complete backup of https://quintessence.jp
Are you over 18 and want to see adult content?
Favourite Annotations
Foodgressing | Vancouver Food, Travel, Lifestyle & Photography Blog
Are you over 18 and want to see adult content?
Pasiunea Pescuitului
Are you over 18 and want to see adult content?
Felújított számítógép, PC, használt TFT, használt monitor, használt laptop, notebook :: PC Aréna Kft.
Are you over 18 and want to see adult content?
Пробактерии - Всё о бактериях и других микроорганизмах
Are you over 18 and want to see adult content?
Best Travel Agency in Sikkim : Adarsh Tours, Treks & Expedition - Sikkim
Are you over 18 and want to see adult content?
Tinkerlust | Luxury Branded Fashion Wanita Baru dan Preloved
Are you over 18 and want to see adult content?
Magazin Virtual la cheie, Soft magazin online
Are you over 18 and want to see adult content?
Digital Marketing Agency Milton Keynes | SF Digital Studios
Are you over 18 and want to see adult content?
Text
THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2021 FINANCIAL ANNOVERA net product revenue increased by $6.5 million to $8.8 million for the first quarter of 2021 as compared to $2.3 million for the first quarter of 2020. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,071 for the first quarter of 2021. The Company expects net revenue per unit for ANNOVERA to averagePRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
SEC FILINGS
May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. 0001193125-21-153419.pdf. 0001193125-21-153419.rtf. 0001193125-21-153419.xls. BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
ROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2021 FINANCIAL ANNOVERA net product revenue increased by $6.5 million to $8.8 million for the first quarter of 2021 as compared to $2.3 million for the first quarter of 2020. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,071 for the first quarter of 2021. The Company expects net revenue per unit for ANNOVERA to averagePRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
SEC FILINGS
May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. 0001193125-21-153419.pdf. 0001193125-21-153419.rtf. 0001193125-21-153419.xls. BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
ROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy ABOUT THERAPEUTICSMD Optimizing health is our goal Empowering her is our purpose. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout thevarious stages of
THERAPEUTICSMD TO REPORT FIRST QUARTER 2021 RESULTS ON MAY Executive Management to Host Conference Call on May 6, 2021 at 8:30 a.m. ET. BOCA RATON, Fla.--(BUSINESS WIRE)--Apr. 29, 2021-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveOUR LEADERSHIP TEAM
The TherapeuticsMD management team has extensive experience and a proven track record of success in product innovation, development, and commercialization, including within the women’s healthcare industry. We believe that our leadership’s ability to leverage our robust intellectual property, product pipeline, and entrepreneurial spiritwill
FINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
KNIGHT AND THERAPEUTICSMD ANNOUNCE HEALTH CANADA APPROVAL MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 21, 2020-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada.In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopauseROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andJOHN MILLIGAN
John Milligan is President of TherapeuticsMD. An experienced, entrepreneurial healthcare executive, Mr. Milligan has more than 20 years of successful sales, management, business development,and operations experience. Throughout his career, he has leveraged his knowledge of the complex healthcare environment to create numerous successful companies.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2021 FINANCIAL ANNOVERA net product revenue increased by $6.5 million to $8.8 million for the first quarter of 2021 as compared to $2.3 million for the first quarter of 2020. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,071 for the first quarter of 2021. The Company expects net revenue per unit for ANNOVERA to averagePRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
SEC FILINGS
May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. 0001193125-21-153419.pdf. 0001193125-21-153419.rtf. 0001193125-21-153419.xls. BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
ROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2021 FINANCIAL ANNOVERA net product revenue increased by $6.5 million to $8.8 million for the first quarter of 2021 as compared to $2.3 million for the first quarter of 2020. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,071 for the first quarter of 2021. The Company expects net revenue per unit for ANNOVERA to averagePRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
SEC FILINGS
May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. 0001193125-21-153419.pdf. 0001193125-21-153419.rtf. 0001193125-21-153419.xls. BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
ROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy ABOUT THERAPEUTICSMD Optimizing health is our goal Empowering her is our purpose. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout thevarious stages of
THERAPEUTICSMD TO REPORT FIRST QUARTER 2021 RESULTS ON MAY Executive Management to Host Conference Call on May 6, 2021 at 8:30 a.m. ET. BOCA RATON, Fla.--(BUSINESS WIRE)--Apr. 29, 2021-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveOUR LEADERSHIP TEAM
The TherapeuticsMD management team has extensive experience and a proven track record of success in product innovation, development, and commercialization, including within the women’s healthcare industry. We believe that our leadership’s ability to leverage our robust intellectual property, product pipeline, and entrepreneurial spiritwill
FINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
KNIGHT AND THERAPEUTICSMD ANNOUNCE HEALTH CANADA APPROVAL MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 21, 2020-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada.In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopauseROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andJOHN MILLIGAN
John Milligan is President of TherapeuticsMD. An experienced, entrepreneurial healthcare executive, Mr. Milligan has more than 20 years of successful sales, management, business development,and operations experience. Throughout his career, he has leveraged his knowledge of the complex healthcare environment to create numerous successful companies.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants.INVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2021 FINANCIAL ANNOVERA net product revenue increased by $6.5 million to $8.8 million for the first quarter of 2021 as compared to $2.3 million for the first quarter of 2020. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,071 for the first quarter of 2021. The Company expects net revenue per unit for ANNOVERA to average THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.BHARAT WARRIER
Her vast experience in large scale transactions across the financial spectrum includes IPO’s, mergers, acquisitions, divestitures, public debt offerings, leveraged buyouts and licensing agreements. Her expertise grew at Anthem where she directed strategic transactions totaling over $78 billion in deal value. Jennifer joinedTherapeuticsMD in
PRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants.INVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2021 FINANCIAL ANNOVERA net product revenue increased by $6.5 million to $8.8 million for the first quarter of 2021 as compared to $2.3 million for the first quarter of 2020. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,071 for the first quarter of 2021. The Company expects net revenue per unit for ANNOVERA to average THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.BHARAT WARRIER
Her vast experience in large scale transactions across the financial spectrum includes IPO’s, mergers, acquisitions, divestitures, public debt offerings, leveraged buyouts and licensing agreements. Her expertise grew at Anthem where she directed strategic transactions totaling over $78 billion in deal value. Jennifer joinedTherapeuticsMD in
PRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy ABOUT THERAPEUTICSMD Optimizing health is our goal Empowering her is our purpose. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout thevarious stages of
PRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
FINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View THERAPEUTICSMD® ANNOUNCES SECOND QUARTER 2020 FINANCIAL TherapeuticsMD® Announces Second Quarter 2020 Financial Results. - 2Q20 total net product revenue of $10.7 million resilient despite COVID-19 pandemic -. - ANNOVERA® prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period-. - IMVEXXY® new prescriptions increased33% for the eight
BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
KNIGHT AND THERAPEUTICSMD ANNOUNCE HEALTH CANADA APPROVAL MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 21, 2020-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada.In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.ROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andBHARAT WARRIER
Her vast experience in large scale transactions across the financial spectrum includes IPO’s, mergers, acquisitions, divestitures, public debt offerings, leveraged buyouts and licensing agreements. Her expertise grew at Anthem where she directed strategic transactions totaling over $78 billion in deal value. Jennifer joinedTherapeuticsMD in
THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveFINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.MARLAN WALKER, J.D.
Marlan Walker is General Counsel at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012. In addition to his experience as an in-house attorney, Mr. Walker has extensive experience in private practice at a number of nationallyPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveFINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.MARLAN WALKER, J.D.
Marlan Walker is General Counsel at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012. In addition to his experience as an in-house attorney, Mr. Walker has extensive experience in private practice at a number of nationallyPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy ABOUT THERAPEUTICSMD Optimizing health is our goal Empowering her is our purpose. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout thevarious stages of
PRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
SEC FILINGS
May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. 0001193125-21-153419.pdf. 0001193125-21-153419.rtf. 0001193125-21-153419.xls. MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required. KNIGHT AND THERAPEUTICSMD ANNOUNCE HEALTH CANADA APPROVAL MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 21, 2020-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada.In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopauseROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andBHARAT WARRIER
Her vast experience in large scale transactions across the financial spectrum includes IPO’s, mergers, acquisitions, divestitures, public debt offerings, leveraged buyouts and licensing agreements. Her expertise grew at Anthem where she directed strategic transactions totaling over $78 billion in deal value. Jennifer joinedTherapeuticsMD in
THERAPEUTICSMD ANNOUNCES FDA APPROVAL OF ANNOVERA The first and only birth control approved as a vaginal system. The first and only patient-controlled, procedure-free, long-acting, reversible prescription birth control product to provide a full year of protection from pregnancyTHERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveFINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.MARLAN WALKER, J.D.
Marlan Walker is General Counsel at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012. In addition to his experience as an in-house attorney, Mr. Walker has extensive experience in private practice at a number of nationallyPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB.THERAPEUTICSMD
An innovative pharmaceutical company exclusively committed to advancing women’s health. Worldwide commercial rights for multiple women’s health products. Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success inwomen’s health.
PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policyINVESTORS & MEDIA
10. Listen to Webcast. TXMD 2021 Q1 Earnings Call. Thursday May 06, 2021 8:30:am EDT. Supporting Materials. Q1 2021 Earnings Presentation 3.9 MB. Listen to Webcast. H.C. Wainwright Global Life Sciences Conference. Tuesday Mar 09, 2021 11:00:am EST. CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveFINANCIAL REPORTS
Filing Group. View. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required.MARLAN WALKER, J.D.
Marlan Walker is General Counsel at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012. In addition to his experience as an in-house attorney, Mr. Walker has extensive experience in private practice at a number of nationallyPRESENTATIONS
NAMS October 2018. A 17β-Estradiol, Softgel, Vaginal Capsule Insert (TX-004HR) had an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate to Severe Dyspareunia. 241.2 KB. Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4-and 10-μg) Estradiol Softgel Capsule Vaginal Insert. 198.3 KB. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy ABOUT THERAPEUTICSMD Optimizing health is our goal Empowering her is our purpose. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout thevarious stages of
PRESS RELEASES
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021. 04/08/21. TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium. 03/02/21. TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 FinancialResults.
BRIAN BERNICK, M.D., F.A.C.O.G. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residencyat
SEC FILINGS
May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. 0001193125-21-153419.pdf. 0001193125-21-153419.rtf. 0001193125-21-153419.xls. MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required. KNIGHT AND THERAPEUTICSMD ANNOUNCE HEALTH CANADA APPROVAL MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 21, 2020-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada.In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopauseROBERT G. FINIZIO
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing andBHARAT WARRIER
Her vast experience in large scale transactions across the financial spectrum includes IPO’s, mergers, acquisitions, divestitures, public debt offerings, leveraged buyouts and licensing agreements. Her expertise grew at Anthem where she directed strategic transactions totaling over $78 billion in deal value. Jennifer joinedTherapeuticsMD in
THERAPEUTICSMD ANNOUNCES FDA APPROVAL OF ANNOVERA The first and only birth control approved as a vaginal system. The first and only patient-controlled, procedure-free, long-acting, reversible prescription birth control product to provide a full year of protection from pregnancyTHERAPEUTICSMD
Highly differentiated products for chronic conditions targeted to large and growing markets. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants.INVESTORS & MEDIA
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts. MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required. BRIAN BERNICK, M.D., F.A.C.O.G. Brian Bernick, M.D., F.A.C.O.G. Co-Founder and Chief Scientific Officer. Dr. Brian Bernick is Co-Founder and Chief Scientific Officerat TherapeuticsMD.
MARLAN WALKER, J.D.
Marlan Walker, J.D. General Counsel. Marlan Walker is General Counsel at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012.PRESENTATIONS
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts.FINANCIAL REPORTS
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effectiveTHERAPEUTICSMD
Highly differentiated products for chronic conditions targeted to large and growing markets. PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy CAREERS | THERAPEUTICSMD TherapeuticsMD Careers Careers. BEWARE OF SCAM TARGETING JOB APPLICANTS. Please click here if you have inquired about a job from TherapeuticsMD, believe you have interviewed with TherapeuticsMD, or believe you have received a job offer from TherapeuticsMD to learn more about a scam that is fraudulently using TherapeuticsMD’s brand to target job applicants.INVESTORS & MEDIA
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts. MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required. BRIAN BERNICK, M.D., F.A.C.O.G. Brian Bernick, M.D., F.A.C.O.G. Co-Founder and Chief Scientific Officer. Dr. Brian Bernick is Co-Founder and Chief Scientific Officerat TherapeuticsMD.
MARLAN WALKER, J.D.
Marlan Walker, J.D. General Counsel. Marlan Walker is General Counsel at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012.PRESENTATIONS
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts.FINANCIAL REPORTS
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts. THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 1, 2020-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020.Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective PRODUCTS | THERAPEUTICSMD 2020 TherapeuticsMD, Inc. All rights reserved. privacy policy | ; terms of use | ; safe harbor | ; trademark policy ABOUT THERAPEUTICSMD Optimizing health is our goal Empowering her is our purpose. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. MEDICAL INFORMATION REQUESTS FORM Medical Information Request Form For Healthcare Providers If you are a patient, please contact your healthcare provider directly. Please note: All fields below are required. BRIAN BERNICK, M.D., F.A.C.O.G. Brian Bernick, M.D., F.A.C.O.G. Co-Founder and Chief Scientific Officer. Dr. Brian Bernick is Co-Founder and Chief Scientific Officerat TherapeuticsMD.
ROBERT G. FINIZIO
Robert G. Finizio Chief Executive Officer, Co-Founder, and Director. Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company.PRESS RELEASES
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts.SEC FILINGS
The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts.BHARAT WARRIER
Jennifer Wilson Vice President, Business Development. Jennifer Wilson began her healthcare career through investment banking, working in the Bank of America Merrill Lynch Healthcare Group. KNIGHT AND THERAPEUTICSMD ANNOUNCE HEALTH CANADA APPROVAL MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 21, 2020-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada.In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause THERAPEUTICSMD ANNOUNCES FDA APPROVAL OF ANNOVERA The first and only birth control approved as a vaginal system. The first and only patient-controlled, procedure-free, long-acting, reversible prescription birth control product to provide a full year of protection from pregnancy* Contact Us |
* Email Alerts
__
* about us
* about
* leadership
* board of directors* partnering
* careers
* Our Mission & Values* products
* Products
* Product Patents
* ANNOVERA®
* BIJUVA®
* BocaGreenMD®
* IMVEXXY®
* vitaMedMD®
* medical affairs
* investors & media
* COVID-19 UPDATE
* Investors & Media
* Press Releases
* Events & Presentations* Stock Information
* Financial History
* Charters & Governance* Analyst Coverage
* Contacts
* Reference Links
* Logos Media Resources* Email Alerts
* Contact Us
* about us
* about
* leadership
* board of directors* partnering
* careers
* Our Mission & Values* products
* Products
* Product Patents
* ANNOVERA®
* BIJUVA®
* BocaGreenMD®
* IMVEXXY®
* vitaMedMD®
* medical affairs
* investors & media
* COVID-19 UPDATE
* Investors & Media
* Press Releases
* Events & Presentations* Stock Information
* Financial History
* Charters & Governance* Analyst Coverage
* Contacts
* Reference Links
* Logos Media Resources* Email Alerts
* Contact Us
Previous
Next
Previous
Next
CORPORATE HIGHLIGHTS An innovative pharmaceutical company exclusively committed to advancing women’s health Worldwide commercial rights for multiple women’s health products Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success in women’s health U.S. commercial infrastructure in place with multiple distributionchannels
THERAPEUTICSMD UPDATE REGARDING COVID-19Click here
for more information 2020 TherapeuticsMD, Inc. All rights reserved.* privacy policy |
* terms of use |
* safe harbor |
* trademark policy
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0